Identification

Name
Ibrutinib
Accession Number
DB09053
Type
Small Molecule
Groups
Approved
Description

Ibrutinib is a small molecule anti-cancer drug that targets B-cell malignancies. In November 2013 ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenström's Macroglobulinemia (WM). Ibrutinib is marketed under the brand Imbruvica® by Janssen Biotech, Inc., but was first designed and synthesized at Celera Genomics in 2007. Ibrutinib was approved for use in chronic graft versus host disease in August 2017 [4].

Structure
Thumb
Synonyms
  • 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
External IDs
CRA-032765 / PC-32765 / PCI 32765 / PCI-32765 / PCI-32765-00
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImbruvicaCapsule140 mgOralJanssen Pharmaceuticals2014-11-19Not applicableCanada
ImbruvicaCapsule140 mg/1OralPharmacyclics2013-11-07Not applicableUs
ImbruvicaCapsule140 mgOralJanssen Cilag International Nv2014-10-21Not applicableEu
ImbruvicaCapsule140 mgOralJanssen Cilag International Nv2014-10-21Not applicableEu
Categories
UNII
1X70OSD4VX
CAS number
936563-96-1
Weight
Average: 440.507
Monoisotopic: 440.196074037
Chemical Formula
C25H24N6O2
InChI Key
XYFPWWZEPKGCCK-GOSISDBHSA-N
InChI
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
IUPAC Name
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
SMILES
NC1=NC=NC2=C1C(=NN2[[email protected]@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1

Pharmacology

Indication

Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenström's Macroglobulinemia (WM). In August 2017, ibrutinib was approved for the treatment of chronic graft versus host disease patients who have failed one or more other therapies [4].

Structured Indications
Pharmacodynamics

In patients with recurrent B-cell lymphoma > 90% occupancy of the BTK active site in peripheral blood mononuclear cells was observed up to 24 hours after ibrutinib doses of ≥ 2.5 mg/kg/day (≥ 175 mg/day for average weight of 70 kg).

Mechanism of action

Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK, leading to its inhibition. BTK plays a role in signalling through the B-cell surface receptors which results in the activation of various pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Ibrutinib has been shown to inhibit malignant B cell proliferation and survival in vivo as well as substrate adhesion and cell migration.

TargetActionsOrganism
ATyrosine-protein kinase BTK
inhibitor
Human
Absorption

Median Tmax of 1-2 hours. Steady-state AUC at 560 mg: 953 ± 705 ng⋅h/mL Steady-state AUC at 420 mg: 680 ± 517 ng⋅h/mL

Volume of distribution

~10000 L at steady-state.

Protein binding

97.3%.

Metabolism

It is metabolized to several metabolites primarily by cytochrome P450, CYP3A, and to a minor extent by CYP2D6. The active metabolite, PCI-45227, is a dihydrodiol metabolite with inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib. The range of the mean metabolite to parent ratio for PCI-45227 at steady-state is 1 to 2.8.

Route of elimination

Feces (80%), urine (10%).

Half life

4-6 hours.

Clearance

~1000 L/h, and is not affected by age or gender.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Abciximab.Approved
AbirateroneThe serum concentration of Ibrutinib can be increased when it is combined with Abiraterone.Approved
AcenocoumarolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ibrutinib.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Acetylsalicylic acid.Approved, Vet Approved
AlprostadilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Alprostadil.Approved, Investigational
AmiodaroneThe serum concentration of Ibrutinib can be increased when it is combined with Amiodarone.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Anagrelide.Approved
AncrodThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Andrographolide.Investigational
Antithrombin III humanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Apixaban.Approved
AprepitantThe serum concentration of Ibrutinib can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Argatroban.Approved, Investigational
ArtemetherThe metabolism of Ibrutinib can be decreased when combined with Artemether.Approved
AtazanavirThe serum concentration of Ibrutinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Ibrutinib can be increased when it is combined with Atomoxetine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Azelastine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ibrutinib.Investigational
BecaplerminThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Becaplermin.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Beraprost.Investigational
BetaxololThe metabolism of Ibrutinib can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ibrutinib.Approved, Investigational
BivalirudinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ibrutinib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Ibrutinib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ibrutinib can be decreased when it is combined with Bosentan.Approved, Investigational
BuflomedilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Buflomedil.Experimental
BupropionThe metabolism of Ibrutinib can be decreased when combined with Bupropion.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Butylphthalide.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ibrutinib.Approved
CangrelorThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Cangrelor.Approved
CarbamazepineThe serum concentration of Ibrutinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CelecoxibThe metabolism of Ibrutinib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ibrutinib can be increased when it is combined with Ceritinib.Approved
CertoparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Certoparin.Approved, Investigational
ChloroquineThe metabolism of Ibrutinib can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe metabolism of Ibrutinib can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Ibrutinib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Cilostazol.Approved
CimetidineThe metabolism of Ibrutinib can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Ibrutinib can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Ibrutinib can be decreased when combined with Citalopram.Approved
Citric AcidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Ibrutinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Ibrutinib can be increased when it is combined with Clemastine.Approved
ClobazamThe metabolism of Ibrutinib can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Ibrutinib can be decreased when combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clopidogrel.Approved, Nutraceutical
CloricromenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Cloricromen.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib.Approved
ClotrimazoleThe serum concentration of Ibrutinib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Ibrutinib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ibrutinib can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Ibrutinib can be increased when it is combined with Conivaptan.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib.Approved
CrizotinibThe serum concentration of Ibrutinib can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ibrutinib.Approved, Investigational
CyclosporineThe serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Ibrutinib.Experimental
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ibrutinib can be decreased when it is combined with Dabrafenib.Approved
DalteparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dalteparin.Approved
DanaparoidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Danaparoid.Approved, Withdrawn
DarexabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Darexaban.Investigational
DarifenacinThe metabolism of Ibrutinib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ibrutinib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ibrutinib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ibrutinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Defibrotide.Approved, Investigational
DelavirdineThe serum concentration of Ibrutinib can be increased when it is combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Ibrutinib.Approved
DesipramineThe metabolism of Ibrutinib can be decreased when combined with Desipramine.Approved
DesirudinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ibrutinib.Approved
DextranThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dextran.Approved, Vet Approved
Dextran 40The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dextran 40.Approved
Dextran 70The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dextran 70.Approved
Dextran 75The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dextran 75.Approved
DicoumarolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dicoumarol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ibrutinib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ibrutinib.Approved
DihydroergotamineThe serum concentration of Ibrutinib can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Ibrutinib can be increased when it is combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Ibrutinib can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ibrutinib.Approved, Investigational
DosulepinThe metabolism of Ibrutinib can be decreased when combined with Dosulepin.Approved
DoxycyclineThe serum concentration of Ibrutinib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Ibrutinib can be increased when it is combined with Dronedarone.Approved
DuloxetineThe metabolism of Ibrutinib can be decreased when combined with Duloxetine.Approved
Edetic AcidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Edoxaban.Approved
EliglustatThe metabolism of Ibrutinib can be decreased when combined with Eliglustat.Approved
EnoxaparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Enoxaparin.Approved
EnzalutamideThe serum concentration of Ibrutinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Eplivanserin.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Epoprostenol.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.Approved, Investigational
ErythromycinThe serum concentration of Ibrutinib can be increased when it is combined with Erythromycin.Approved, Vet Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ethyl biscoumacetate.Withdrawn
Ferulic acidThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ferulic acid.Experimental
FingolimodIbrutinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Fluconazole.Approved
FluindioneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Fluindione.Investigational
FluoxetineThe metabolism of Ibrutinib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe serum concentration of Ibrutinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Fondaparinux.Investigational
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Fondaparinux sodium.Approved, Investigational
FosamprenavirThe serum concentration of Ibrutinib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ibrutinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ibrutinib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ibrutinib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Ibrutinib.Investigational
GabexateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Gabexate.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ibrutinib.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ibrutinib.Experimental
HaloperidolThe metabolism of Ibrutinib can be decreased when combined with Haloperidol.Approved
HeparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Heparin.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibrutinib.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibrutinib.Approved, Withdrawn
HydroxytyrosolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydroxytyrosol.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ibudilast.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Icosapent ethyl.Approved, Nutraceutical
IdelalisibThe serum concentration of Ibrutinib can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ifetroban.Investigational
IloprostThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Ibrutinib can be increased when it is combined with Imatinib.Approved
ImipramineThe metabolism of Ibrutinib can be decreased when combined with Imipramine.Approved
IndinavirThe serum concentration of Ibrutinib can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Indobufen.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Ibrutinib.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibrutinib.Investigational
IsavuconazoniumThe serum concentration of Ibrutinib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Ibrutinib can be decreased when combined with Isoniazid.Approved
IsradipineThe serum concentration of Ibrutinib can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ibrutinib can be increased when it is combined with Ivacaftor.Approved
KetanserinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ketanserin.Investigational
KetoconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Ketoconazole.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ibrutinib.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Leflunomide.Approved, Investigational
LepirudinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Lepirudin.Approved
LetaxabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Letaxaban.Investigational
Linseed oilLinseed oil may increase the antiplatelet activities of Ibrutinib.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Linsidomine.Experimental
LopinavirThe serum concentration of Ibrutinib can be increased when it is combined with Lopinavir.Approved
LorcaserinThe metabolism of Ibrutinib can be decreased when combined with Lorcaserin.Approved
LovastatinThe serum concentration of Ibrutinib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ibrutinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ibrutinib can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Ibrutinib can be decreased when combined with Manidipine.Approved, Investigational
MelagatranThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Melagatran.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibrutinib.Investigational, Withdrawn
MethadoneThe metabolism of Ibrutinib can be decreased when combined with Methadone.Approved
MethotrimeprazineThe metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ibrutinib.Experimental
MetoprololThe metabolism of Ibrutinib can be decreased when combined with Metoprolol.Approved, Investigational
MidostaurinThe metabolism of Ibrutinib can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Ibrutinib can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Milrinone.Approved
MirabegronThe metabolism of Ibrutinib can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Ibrutinib can be decreased when it is combined with Mitotane.Approved
NadroparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Naftopidil.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Ibrutinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ibrutinib can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ibrutinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Ibrutinib can be increased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Ibrutinib can be decreased when combined with Nicardipine.Approved
NilotinibThe serum concentration of Ibrutinib can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nitroaspirin.Investigational
OlaparibThe serum concentration of Ibrutinib can be increased when it is combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Ibrutinib.Experimental, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ibrutinib.Approved, Nutraceutical
OsimertinibThe serum concentration of Ibrutinib can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ibrutinib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ibrutinib.Approved, Vet Approved
PalbociclibThe serum concentration of Ibrutinib can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Ibrutinib can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Ibrutinib can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ibrutinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
Pentaerythritol TetranitrateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentaerythritol Tetranitrate.Approved
PentobarbitalThe serum concentration of Ibrutinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentoxifylline.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ibrutinib.Experimental
PhenindioneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Ibrutinib can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Ibrutinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibrutinib.Approved, Investigational
PosaconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Prasugrel.Approved
PrimidoneThe serum concentration of Ibrutinib can be decreased when it is combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Ibrutinib can be decreased when combined with Promazine.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ibrutinib.Experimental
Protein CThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Protein C.Approved
Protein S humanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Protocatechualdehyde.Approved
QuinidineThe metabolism of Ibrutinib can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ibrutinib can be decreased when combined with Quinine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibrutinib.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ramatroban.Investigational
RanolazineThe serum concentration of Ibrutinib can be increased when it is combined with Ranolazine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Reviparin.Approved, Investigational
RibociclibThe serum concentration of Ibrutinib can be increased when it is combined with Ribociclib.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ridogrel.Approved
RifabutinThe serum concentration of Ibrutinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ibrutinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ibrutinib can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ibrutinib.Investigational
RitonavirThe metabolism of Ibrutinib can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rivaroxaban.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Ibrutinib.Approved
RolapitantThe metabolism of Ibrutinib can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Ibrutinib can be decreased when combined with Ropinirole.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Ibrutinib.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Ibrutinib.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ibrutinib.Approved
SaquinavirThe serum concentration of Ibrutinib can be increased when it is combined with Saquinavir.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sarpogrelate.Investigational
SertralineThe metabolism of Ibrutinib can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Ibrutinib can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ibrutinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ibrutinib can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibrutinib.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ibrutinib.Investigational
SRT501The risk or severity of adverse effects can be increased when Ibrutinib is combined with SRT501.Investigational
St. John's WortThe serum concentration of Ibrutinib can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Ibrutinib can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe serum concentration of Ibrutinib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulodexide.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibrutinib.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Ibrutinib.Investigational
TelaprevirThe serum concentration of Ibrutinib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Ibrutinib can be increased when it is combined with Telithromycin.Approved
TerbinafineThe metabolism of Ibrutinib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tesmilifene.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Ibrutinib.Investigational
ThioridazineThe metabolism of Ibrutinib can be decreased when combined with Thioridazine.Approved, Withdrawn
TicagrelorThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ticlopidine.Approved
TipranavirThe metabolism of Ibrutinib can be decreased when combined with Tipranavir.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tirofiban.Approved
TocilizumabThe serum concentration of Ibrutinib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibIbrutinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Ibrutinib can be decreased when combined with Tranylcypromine.Approved
TrapidilThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ibrutinib.Approved, Investigational
TriflusalThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Triflusal.Approved, Investigational
TroxerutinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Troxerutin.Investigational
VenlafaxineThe serum concentration of Ibrutinib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Ibrutinib can be increased when it is combined with Verapamil.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Ibrutinib.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Vorapaxar.Approved
VoriconazoleThe serum concentration of Ibrutinib can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Warfarin.Approved
XimelagatranThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Ibrutinib.Approved
ZiprasidoneThe serum concentration of Ibrutinib can be increased when it is combined with Ziprasidone.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Ibrutinib.Approved
Food Interactions
  • Administration with food increases ibrutinib exposure approximately 2-fold compared with administration after overnight fasting.

References

General References
  1. Bagcchi S: Ibrutinib in pretreated Waldenstrom's macroglobulinaemia. Lancet Oncol. 2015 May;16(5):e204. doi: 10.1016/S1470-2045(15)70185-3. Epub 2015 Apr 16. [PubMed:25892147]
  2. Kim ES, Dhillon S: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3. [PubMed:25802231]
  3. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
  4. FDA: Ibrutinib cGVHD approval [Link]
External Links
KEGG Drug
D10223
PubChem Compound
24821094
PubChem Substance
310264995
ChemSpider
26637187
BindingDB
50357312
ChEBI
76612
ChEMBL
CHEMBL1873475
PharmGKB
PA166121346
HET
1E8
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibrutinib
ATC Codes
L01XE27 — Ibrutinib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
4ifg / 4rz7 / 5p9i
FDA label
Download (579 KB)
MSDS
Download (24.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentMalignant Neoplasms Stated as Primary Lymphoid Haematopoietic / Mantle Cell Lymphoma (MCL)1
0RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentCD20 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
1Active Not RecruitingTreatmentCD20 Positive / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1Active Not RecruitingTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentMalignancies, Hematologic1
1Active Not RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentRecurrent Mantle Cell Lymphoma / T(11;14)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia1
1CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (SLL)1
1CompletedTreatmentHealthy Participants2
1CompletedTreatmentHealthy Volunteers6
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentLeukemia, B-Cell / Lymphoma, B-Cell1
1CompletedTreatmentRecurrent Mature B-cell Neoplasms1
1Not Yet RecruitingTreatmentBurkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingOtherLeukemia, Lymphocytic, Chronic, B-Cell1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Mediastinal Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Waldenstrom Macroglobulinemia / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma1
1RecruitingTreatmentCD20 Positive / HIV Positivity / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentCancers2
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)3
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Mantle Cell Lymphoma (MCL)1
1RecruitingTreatmentChronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts in Transformation / Secondary Myelodysplastic Syndromes1
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1RecruitingTreatmentLeukemia, Lymphocytic1
1RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentLymphoma, Mantle-Cell / Recurrent Lymphoma, Mantle-Cell1
1RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia1
1RecruitingTreatmentRecurrent Chronic Lymphoid Leukemia1
1RecruitingTreatmentRefractory Diffuse Large B-Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentRelapsed and Refractory T-cell Lymphoma / T-Cell Lymphomas1
1SuspendedTreatmentPrimary Central Nervious System Lymphoma1
1TerminatedTreatmentAdult B Acute Lymphoblastic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Human Immunodeficiency Virus (HIV) Infections / Intraocular Lymphoma / Multicentric Angiofollicular Lymphoid Hyperplasia / Nodal Marginal Zone Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Plasma Cell Myeloma / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1WithdrawnTreatmentCore: Relapsed or Refractory Diffuse Large B-Cell Lymphoma / Module 1: Non-GCB Diffuse Large B-Cell Lymphoma1
1WithdrawnTreatmentFollicular Lymphoma (FL) / Leukemia, Lymphocytic, Chronic, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Mantle-Cell1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Mantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Refractory Chronic Lymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed1
1, 2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
1, 2Active Not RecruitingTreatmentLeukemias1
1, 2Active Not RecruitingTreatmentLung Cancers1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Prolymphocyctic Leukemia / Richter's Transformation / Small Lymphocytic Lymphoma (SLL)1
1, 2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (SLL)1
1, 2CompletedTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas1
1, 2Not Yet RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma (SLL)1
1, 2Not Yet RecruitingTreatmentCarcinoma, Colorectal / Colon Diseases / Colorectal Cancers / Malignant Neoplasm of Colon1
1, 2Not Yet RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1, 2Not Yet RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell / Small Lymphocytic Lymphoma (SLL)1
1, 2Not Yet RecruitingTreatmentLymphoma, Mantle-Cell1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Mantle Cell Lymphoma (MCL)1
1, 2RecruitingTreatmentColorectal Adenocarcinoma (CRC) / Gastric Adenocarcinoma / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
1, 2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1, 2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell / Malignant Lymphomas1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
1, 2RecruitingTreatmentMantle Cell Lymphoma (MCL)2
1, 2RecruitingTreatmentMetastatic Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2RecruitingTreatmentMultiple Myeloma (MM)2
1, 2RecruitingTreatmentNeoplasms, Hematologic1
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2RecruitingTreatmentProstate Cancer1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentRefractory Diffuse Large B-Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma1
1, 2RecruitingTreatmentRefractory Follicular Lymphoma / Relapsed Follicular Lymphoma1
1, 2RecruitingTreatmentRefractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) / Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)1
1, 2RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
1, 2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentAdult Patients / Chronic Lymphocyte Leukemia1
2Active Not RecruitingTreatmentCLL (Chronic Lymphocytic Leukemia) / Leukemia, Lymphocytyc / Leukemias / SLL (Small Lymphocytic Lymphoma)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leucemia1
2Active Not RecruitingTreatmentChronic Lymphocytic Leucemia / Chronic Lymphocytic Leukaemia (CLL)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Primary Lymphoid Haematopoietic Neoplasms / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukemia With 17p Deletion / Small Lymphocytic Lymphoma With 17p Deletion1
2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentIndolent Non-Hodgkin's Lymphomas1
2Active Not RecruitingTreatmentIntraocular Lymphoma / Primary Central Nervous Lymphoma1
2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory/Relapsed Chronic Lymphocytic Leukemia1
2Active Not RecruitingTreatmentLeukemias2
2Active Not RecruitingTreatmentLymphoma, B-Cell / Marginal Zone Lymphoma1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentRecurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Refractory Follicular Lymphoma1
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)2
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentLymphoma, Mantle-Cell1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMantle Cell Lymphoma (MCL)2
2Enrolling by InvitationTreatmentB-Cell Chronic Lymphocytic Leukemia / B-Cell Diffuse Lymphoma / Burkitt's Lymphoma / Diffuse Well-differentiated Lymphocytic Lymphoma / Follicular Lymphoma (FL) / Lymphoma, B Cell / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
2Not Yet RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive1
2Not Yet RecruitingTreatmentAmyloidosis / Immunoglobulin Light Chain Deposition1
2Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Small Lymphocytic / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer / Mantle Cell Lymphoma (MCL)2
2Not Yet RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingPreventionAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic Cell Transplantation Recipient / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentAnaphylaxis Food / Food Allergy1
2RecruitingTreatmentAssociated Clonal Hematological Non-Mast-Cell Lineage Disease / Malignant mast cell neoplasm / Systemic Mastocytosis / Systemic mastocytosis with associated hematological neoplasm1
2RecruitingTreatmentBlastoid Variant Mantle Cell Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Follicular Lymphoma / Refractory Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentCLL (Chronic Lymphocytic Leukemia) / SLL (Small Lymphocytic Lymphoma)1
2RecruitingTreatmentCLL / SLL1
2RecruitingTreatmentCarcinoid Tumors / Pancreatic NET1
2RecruitingTreatmentCentral Nervous System Lymphoma1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias3
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentClassical Hodgkin Lymphoma1
2RecruitingTreatmentClassical Hodgkin Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2RecruitingTreatmentDiffuse Large B-cell Lymphoma Recurrent / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas1
2RecruitingTreatmentGastrooesophageal Cancer1
2RecruitingTreatmentHairy Cell Leukemia (HCL) / Hairy Cell Leukemia Variant1
2RecruitingTreatmentHigh Risk Smoldering Multiple Myeloma1
2RecruitingTreatmentLeukemia, Lymphoblastic, Chronic1
2RecruitingTreatmentLeukemia, Lymphocytic, Chronic1
2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
2RecruitingTreatmentLymphoma, B-Cell, Marginal Zone1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Lymphomas4
2RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2RecruitingTreatmentMetastatic Melanoma / Recurrent Melanoma of the Skin / Stage IV Skin Melanoma1
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentNodular Lymphocyte-Predominant Hodgkin's Lymphoma1
2RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Nodal Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Recurrent Splenic Marginal Zone Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Nodal Marginal Zone Lymphoma / Refractory Small Lymphocytic Lymphoma / Refractory Splenic Marginal Zone Lymphoma / Richter's Syndrome / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
2RecruitingTreatmentRecurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
2RecruitingTreatmentRecurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentRecurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentRelapsed/Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentRichter's Syndrome1
2RecruitingTreatmentStage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2SuspendedTreatmentMetastatic Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma / Stages III Skin Melanoma1
2TerminatedTreatmentAdult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Recurrent Adult Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Non-Hodgkin's Lymphoma (NHL) / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
2WithdrawnTreatmentLung Cancer, Nonsmall Cell, Stage I1
2, 3Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
3Active Not RecruitingTreatmentAnemias / Chronic Lymphocytic Leukaemia (CLL) / Fever, Sweats, and Hot Flashes / Hepatomegaly / Lymphadenopathy / Lymphocytosis / Small Lymphocytic Lymphoma (SLL) / Splenomegaly / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma / Thrombocytopenias / Tiredness / Weight Changes1
3Active Not RecruitingTreatmentCD19 Positive / CD20 Positive / CD5 Positive / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Small-Cell1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)3
3Active Not RecruitingTreatmentMalignant Lymphomas2
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)2
3Active Not RecruitingTreatmentRelapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
3Enrolling by InvitationTreatmentChronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma (SLL)1
3Not Yet RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
3RecruitingTreatmentActivated B-Cell-Like Diffuse Large B-Cell Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma, Not Otherwise Specified / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3RecruitingTreatmentChronic Graft Versus Host Disease1
3RecruitingTreatmentChronic Hepatitis B Infection / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Indolent B-cell Lymphomas / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)3
3RecruitingTreatmentLymphoma, Mantle-Cell1
3RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentTreatment Naive Follicular Lymphoma1
3RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
3WithdrawnTreatmentMantle Cell Lymphoma (MCL)1
4Active Not RecruitingTreatmentRelapsed or Refractory Mantle Cell Lymphoma1
4Not Yet RecruitingOtherLeukemia, Lymphocytic, Chronic, B-Cell1
4RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemia, B-Cell / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
Not AvailableActive Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
Not AvailableApproved for MarketingNot AvailableB-Cell Chronic Lymphocytic Leukemia1
Not AvailableRecruitingNot AvailableChronic Lymphocytic Leukaemia (CLL)2
Not AvailableRecruitingTreatmentFollicular Lymphoma (FL) / Follicular Lymphoma Grade IIIa / Follicular Lymphoma, Grade 1 / Follicular Lymphoma, Grade 21
Not AvailableRecruitingTreatmentRecurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral140 mg
CapsuleOral140 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8476284No2006-12-282026-12-28Us
US8703780No2006-12-282026-12-28Us
US8754090No2011-06-032031-06-03Us
US8497277No2006-12-282026-12-28Us
US9125889No2011-06-032031-06-03Us
US8999999No2011-06-032031-06-03Us
US8697711No2006-12-282026-12-28Us
US8754091No2006-12-282026-12-28Us
US9181257No2006-12-282026-12-28Us
US8957079No2006-12-282026-12-28Us
US8008309No2006-12-282026-12-28Us
US8735403No2006-12-282026-12-28Us
US9296753No2013-10-302033-10-30Us
US7514444No2006-12-282026-12-28Us
US9540382No2013-08-182033-08-18Us
US8952015No2006-12-282026-12-28Us
US9725455No2013-06-032033-06-03Us
US9713617No2013-06-032033-06-03Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0203 mg/mLALOGPS
logP2.76ALOGPS
logP3.63ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)19.7ChemAxon
pKa (Strongest Basic)6.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.16 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity138.07 m3·mol-1ChemAxon
Polarizability47.84 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Diarylethers / Phenylpyrazoles / Pyrazolo[3,4-d]pyrimidines / N-acylpiperidines / Phenol ethers / Phenoxy compounds / Aminopyrimidines and derivatives / Imidolactams / Heteroaromatic compounds / Tertiary carboxylic acid amides
show 8 more
Substituents
Diphenylether / Diaryl ether / Phenylpyrazole / N-acyl-piperidine / Pyrazolo[3,4-d]pyrimidine / Pyrazolopyrimidine / Phenoxy compound / Phenol ether / Aminopyrimidine / Piperidine
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, N-acylpiperidine, aromatic amine, pyrazolopyrimidine, acrylamides (CHEBI:76612)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein tyrosine kinase activity
Specific Function
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately le...
Gene Name
BTK
Uniprot ID
Q06187
Uniprot Name
Tyrosine-protein kinase BTK
Molecular Weight
76280.71 Da
References
  1. Kim ES, Dhillon S: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3. [PubMed:25802231]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]

Drug created on May 07, 2015 13:33 / Updated on November 22, 2017 12:37